MAP1LC3A and Parkinson disease: Compound mT1 was found to promote mitochondrial degradation through LC3 and autophagy-related proteins (ATGs), mitigating disease phenotypes in Parkinson’s disease (PD) cell models and Down syndrome (DS) organ models [40].